SCHEMBL499149

SCHEMBL499149

Cc1ccc(Cl)cc1C(CCCOC(=O)NC(C)(C)C)OCCN

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.35
NPC1 O15118 2/20 0.35
HPGD P15428 2/20 0.35
RAB9A P51151 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
ALDH1A1 P00352 4/20 0.33
LMNA P02545 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MDM2 Q00987 5/20 0.33
CNR1 P21554 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL498591 0.91 PSEN1 (0.37) SMN1; SMN2NPC1HPGDRAB9ACYP1A2
SCHEMBL4754336 0.76 KMT2A (0.37) SMN1; SMN2NPC1HPGDRAB9ACYP1A2
SCHEMBL499213 0.73 UTS2R (0.35) KDM4EMAPT
SCHEMBL8080309 0.67 NOS2 (0.41) SMN1; SMN2HPGDCYP1A2CYP2C9CYP2C19
SCHEMBL499262 0.67 NOS2 (0.41) SMN1; SMN2HPGDCYP1A2CYP2C9CYP2C19
SCHEMBL4755992 0.66 NOS2 (0.43) SMN1; SMN2HPGDCYP1A2ALDH1A1LMNA
SCHEMBL2704670 0.66 EPHX1 (0.37) CYP1A2
SCHEMBL2703359 0.66 ALDH1A1 (0.33) SMN1; SMN2ALDH1A1LMNACNR1MAPT
SCHEMBL1205899 0.64 EPHX1 (0.40) CYP1A2
SCHEMBL27953236 0.64 MAPT (0.43) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106221-B2 Renin inhibitors VITAE PHARMACEUTICALS, INC. (US) 2012-01-31 US disclosed
US-20100144825-A1 Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2010-06-10 US disclosed
WO-2008156816-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144825-A1 Renin Inhibitors ACE, REN, DNPEP SMN1; SMN2 3254/4885NPC1 898/4885HPGD 579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.